<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Numerous studies demonstrate <z:chebi fb="67" ids="50114">oestrogen</z:chebi>'s neuroprotective effect in <z:hpo ids='HP_0001297'>stroke</z:hpo> models, although the mechanisms are unclear </plain></SENT>
<SENT sid="1" pm="."><plain>Since <z:chebi fb="67" ids="50114">oestrogen</z:chebi> is an <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, we tested the hypothesis that <z:chebi fb="67" ids="50114">oestrogen</z:chebi> reduces <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced damage by reducing free radical damage, particularly <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Sprague-Dawley rats were ovariectomised and a <z:chebi fb="0" ids="16469">17beta-oestradiol</z:chebi> (0.25 mg, 21 day release) or placebo pellet implanted subcutaneously </plain></SENT>
<SENT sid="3" pm="."><plain>Two weeks later, permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) was induced by intraluminal filament </plain></SENT>
<SENT sid="4" pm="."><plain>At 2 and 24 h post-MCAO, neurological deficits were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>At the 24 h end point, plasma <z:chebi fb="0" ids="23965">oestradiol</z:chebi> was measured and brain sections stained with <z:chebi fb="1" ids="51686">haematoxylin</z:chebi> and eosin or <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation marker, 4-hydroxynonenol (4-HNE) immunohistochemistry carried out to measure <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and volume of tissue displaying oxidative damage, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Plasma <z:chebi fb="0" ids="16469">17beta-oestradiol</z:chebi> in <z:chebi fb="0" ids="23965">oestradiol</z:chebi> and placebo groups was 72.6+/-38.0 and 9.3+/-7.4 pg/ml (mean+/-SD), respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was significantly increased (118%) with <z:chebi fb="0" ids="23965">oestradiol</z:chebi> treatment (<z:chebi fb="0" ids="23965">oestradiol</z:chebi>=124+/-84.5, placebo=57+/-46.4 mm3, mean+/-SD, P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>The relationship between 4-HNE and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was significantly influenced by <z:chebi fb="0" ids="16469">17beta-oestradiol</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Neurological deficits were similar between groups (<z:chebi fb="0" ids="23965">oestradiol</z:chebi> median=13, placebo=14, max score=33) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Two week pre-treatment with a high physiological dose of <z:chebi fb="0" ids="16469">17beta-oestradiol</z:chebi> increased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after permanent MCAO </plain></SENT>
<SENT sid="11" pm="."><plain>Although contrary to our original hypothesis, this result demonstrates that <z:chebi fb="67" ids="50114">oestrogen</z:chebi> does have the capacity to promote detrimental actions in the <z:hpo ids='HP_0001297'>stroke</z:hpo>-injured brain </plain></SENT>
<SENT sid="12" pm="."><plain>Given the wide use of <z:chebi fb="67" ids="50114">oestrogen</z:chebi> (contraception, <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> and menopause), more research to clarify the influence of <z:chebi fb="67" ids="50114">oestrogen</z:chebi> on brain injury is urgently required </plain></SENT>
</text></document>